thought call
gilead strong perform guidanc rais direct distinguish
biotech peer far earn season view address
residu concern strength durabl core hiv busi importantli
biktarvi launch deservedli receiv much investor attent given
impress launch rest taf portfolio also shown
resili pace y/i growth even legaci hiv portfolio truvada
benefit increas prep use descovi posit captur
prep share potenti follow long-act inject overal
attent clearli away hep upsid driver solidli hiv near-
long-term yescarta car-t platform horizon
seem straightforward gilead transit posit growth still
question rest pipelin opportun nash unclear
filgotinib face competit environ conced departur ceo
john milligan ad anoth layer uncertainti said attract
multipl estim vs peer clear revenu growth driver
pipelin catalyst option next month remain bullish
share re-rat cycl maintain ow
rate increas pt previous
pipelin updat catalyst rich phase filgotinib ra studi finch
remain track read potenti file late earli
enrol complet phase uc like follow
crohn nash phase selonsertib studi stellar stellar
remain track data phase descovi prep trial plan
model chang follow call adjust forecast
increas total revenu outlook respect vs
prior revis opex tax project estim
adjust ep respect vs prior
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight gilead move beyond
declin hcv franchis diversifi
oncolog car-t creat intermedi term
visibl could return growth hiv
stabl bictegravir potenti drive
share gain car-t earli stage technolog
hematolog expans solid tumor ad
valu
modest declin hcv robust uptak
taf regimen hiv pipelin success non-
virolog agent larg discount share
would drive upsid de-risk axi-cel addit
hematolog success solid tumor
price pressur drive faster declin hcv
diminish cash flow therebi affect abil
busi develop hiv gener
larger impact expect new taf regimen
experi limit uptak car-t fail expand
price target updat price target vs prior base sum-of-the-part
approach estim npv valu key franchis use wacc vs
prior differ growth rate major product assumpt valu hiv
vs prior hcv car-t product vs
prior pipelin vs prior net cash vs
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
